New nasal spray for allergic rhinitis; weight management drug indication is expanded to include teens; monkeypox vaccine access; COVID-19 antibody shelf-life extension; JUUL banned in the US.
Individual consumers are not restricted from having or using JUUL products; however, the Agency will ensure compliance by retailers.
Skyrizi gains new approval; the USPSTF make recommendations on multivitamin use to prevent CVD and cancer; an FDA Panel vote on pimavanserin efficacy for treating hallucinations associated with Alzheimer disease psychosis; Phexxi analysed in over 1000 patients; and Vaxneuvance approved for some pediatrics.
The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.
FDA panel vote on COVID-19 vaccines for young children; new drug approved to treat alopecia; Paxlovid tested in standard risk individuals.
The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments.
Ukoniq has been withdrawn by the FDA; Drug pipeline news in asthma, dermatology and oncology; And there’s positive results for a novel postpartum depression treatment.
The latest guidance for COVID-19 treatment Paxlovid following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; COVID-19 vaccine efficacy update for those aged under 5; And the latest on Monkeypox.
Teva is voluntarily recalling a single lot of Anagrelide Capsules, USP 0.5mg, due to dissolution failure that was detected during a routine stability test.
